TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07190196: A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease

Sponsor: Sanofi · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 124 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT07190196 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07190196 Rescue Dossier →